Literature DB >> 15377885

Terlipressin in catecholamine-resistant septic shock patients.

Marc Leone1, Jacques Albanèse, Anne Delmas, Wajdi Chaabane, Franck Garnier, Claude Martin.   

Abstract

To determine the effects on hemodynamics, laboratory parameters, and renal function of terlipressin used in septic-shock patients with hypotension not responsive to high-dose norepinephrine (>2.0 microg x kg(-1) x min(-1)) and dopamine (25 microg x kg(-1) x min(-1)), a prospective, open-label study was carried out in 17 patients. Patients received one or two boluses of 1 mg of terlipressin. In all patients terlipressin induced a significant increase in mean arterial pressure (MAP), systemic vascular resistance, pulmonary vascular resistance, and left and right ventricular stroke work. The increase in MAP was accompanied by a significant decrease in heart rate and cardiac index, but stroke volume remained unchanged. Oxygen delivery and consumption were significantly decreased. Blood lactate concentrations significantly decreased over the study period. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly increased. Thrombocytes were significantly decreased. No change in prothrombin time was observed. Renal function, assessed by urine flow and creatinine clearance, was significantly improved. Pulmonary function assessed by Pao2/Fio2 ratio was not affected. A significant reduction in norepinephrine and dopamine infusion rates was observed in all patients. Eight patients died during their ICU stay from late multiple organ failure. Within the limitations of the present study (open-label design, small group of patients), it can be concluded that in septic shock patients with hypotension nonresponsive to fluid resuscitation and high-dose vasopressors, terlipressin can be effective to restore MAP. Cardiac index should be closely monitored because it was significantly decreased by terlipressin. Renal function was significantly improved. Mesenteric circulation was not evaluated, but hepatic function was altered during the study period. Further studies are required to determine whether terlipressin is safe in terms of outcome in septic shock patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377885     DOI: 10.1097/01.shk.0000136097.42048.bd

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  29 in total

1.  Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia.

Authors:  Matthias Lange; Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Gabriele Köhler; Tim G Kampmeier; Hugo Van Aken; Martin Westphal
Journal:  Inflamm Res       Date:  2010-12-29       Impact factor: 4.575

2.  Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study.

Authors:  Georgios Papadopoulos; Eleni Sintou; Stavros Siminelakis; Efstratios Koletsis; Nikolaos G Baikoussis; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-03-28       Impact factor: 1.637

3.  Terlipressin as a first choice in septic shock-not yet.

Authors:  Daniel Lima Rocha; Fabio Tanzillo Moreira; Ary Serpa Neto
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

4.  Vasopressin analogues and V1a receptor agonists in septic shock.

Authors:  Marc O Maybauer; Dirk M Maybauer
Journal:  Inflamm Res       Date:  2011-05       Impact factor: 4.575

5.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.

Authors:  Andrea Morelli; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Alessandra Bachetoni; Mariadomenica D'Alessandro; Hugo Van Aken; Paolo Pietropaoli; Martin Westphal
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

Review 6.  The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients.

Authors:  E Christiaan Boerma; Can Ince
Journal:  Intensive Care Med       Date:  2010-09-02       Impact factor: 17.440

7.  Current place of vasopressin analogues in the treatment of septic shock.

Authors:  Christian Ertmer; Sebastian Rehberg; Andrea Morelli; Martin Westphal
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

8.  Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children.

Authors:  Dincer Yildizdas; Hacer Yapicioglu; Umit Celik; Yasar Sertdemir; Emre Alhan
Journal:  Intensive Care Med       Date:  2007-12-19       Impact factor: 17.440

Review 9.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

10.  Terlipressin or europressin?

Authors:  Marc Leone
Journal:  Crit Care       Date:  2009-10-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.